However, since tumor growth is typically observed in younger patients with higher GH levels, the 5–10% increase in tumor volume observed during pegvisomant monotherapy is considered more likely to reflect the natural progression of aggressive tumors or a rebound effect after discontinuing prior SRL treatment (35–38). The gene discussed is GH1; the disease is neoplasm.